LKLakshmi Krishnan

Lakshmi Krishnan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lakshmi Krishnan has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Roles of natural resistance‐associated macrophage protein‐1 in modulating bacterial distribution and immune responses during Salmonella enterica serovar Typhimurium infection in murine pregnancy

    by Gerard Agbayani, Kristina Clark, Subash Sad, Shawn P. Murphy, Lakshmi Krishnan

    Problem: Salmonella enterica serovar Typhimurium (S.Tm) infection in Nramp1+/+ mice during pregnancy can lead to profound bacterial growth in the feto‐placental unit and adverse pregnancy outcomes, including fetal loss, maternal illness and death. The kinetics and mechanisms by which S.Tm gains entry within individual feto‐placental unit, and disseminates through tissues leading to placental resorption and fetal demise remain unclear.Method of Study: Mice were systemically infected with S.Tm. Bacterial burden within spleen and individual placentas, and placental/fetal resorptions were quantified. Flow cytometric analysis of immune cell types in the spleen and individual placentas was performed. Cytokine expression in maternal serum was determined through cytometric bead array.Results: Systemic infection with S.Tm resulted in preferential bacterial proliferation in placentas compared to the spleen in Nramp1+/+ mice. At 24 h post‐infection, the mean infection rate of individual placentas per mouse was ∼50%, increasing to >75% by 72 h post‐infection, suggesting that initial infection in few sites progresses to rapid spread of infection through the uterine milieu. This correlated with a steady increase in placental/fetal resorption rates. Placental infection was associated with local increased neutrophil percentages, whereas numbers and percentages in the spleen remained unchanged, suggesting dichotomous modulation of inflammation between the systemic compartment and the feto‐maternal interface. Reduced survival rates of pregnant mice during infection correlated with decreased serum IFN‐γ but increased IL‐10 levels relative to non‐pregnant controls.Conclusion: Pregnancy compromises host resistance conferred by Nramp1 against S.Tm through compartment‐specific regulation of maternal and placental cellular responses, and modulation of systemic cytokine expression.


  • Open Access

    Maternal Immune Cell and Cytokine Profiles to Predict Cardiovascular Risk Six Months after Preeclampsia

    by Malia S. Q. Murphy, Samantha J. Benton, Brian Cox, Kara Nerenberg, Scott McComb, Lakshmi Krishnan, Risini D. Weeratna, Jean-François Paré, Alysha L. J. Dingwall-Harvey, Shannon A. Bainbridge, et al.

    Women who develop preeclampsia (PE) are at high risk for cardiovascular disease (CVD). Early identification of women with PE who may benefit the most from early cardiovascular risk screening and interventions remains challenging. Our objective was to assess whether cytokine and immune cell profiles after PE are helpful in distinguishing women at low and high CVD risk at 6-months postpartum. Individuals who developed PE were followed for immune cell phenotyping and plasma cytokine quantification at delivery, at 3-months, and at 6-months postpartum. Lifetime CVD risk was assessed at 6-months postpartum, and the immune cell and cytokine profiles were compared between risk groups at each time point. Among 31 participants, 18 (58.1%) exhibited high CVD-risk profiles at 6-months postpartum. The proportion of circulating NK-cells was significantly lower in high-risk participants at delivery (p = 0.04). At 3-months postpartum, high-risk participants exhibited a lower proportion of FoxP3+ regulatory T-cells (p = 0.01), a greater proportion of CD8+ T cells (p = 0.02) and a lower CD4+:CD8+ ratio (p = 0.02). There were no differences in immune cell populations at 6-months postpartum. There were no differences in plasma cytokines levels between risk groups at any time point. Subtle differences in immune cell profiles may help distinguish individuals at low and high CVD risk in the early postpartum period and warrants further investigation.


  • IFN‐alpha receptor deficiency enhances host resistance to oral Salmonella enterica serovar Typhimurium infection during murine pregnancy

    by Gerard Agbayani, Kristina Clark, Jagdeep K. Sandhu, Melissa Hewitt, Subash Sad, Shawn P. Murphy, Lakshmi Krishnan

    Problem: Maternal tolerance during pregnancy increases the risk of infection with certain intracellular pathogens. Systemic Salmonella enterica serovar Typhimurium (S.Tm) infection during pregnancy in normally resistant 129X1/SvJ mice leads to severe placental infection, as well as fetal and maternal deaths. However, the effect of oral infection with S.Tm in pregnant mice and the roles of infection‐induced inflammation and cell death pathways in contributing to susceptibility to infection are unclear.Method of Study: Non‐pregnant and pregnant C57BL/6J wild‐type (WT) and cell death pathway‐altered mice (IFNAR1−/−, Caspase‐1, 11−/−, RIP3−/−) were infected orally with S.Tm. Host survival and fetal resorption were determined. Bacterial burden in mesenteric lymph nodes (MLNs), spleen, liver, and placentas was enumerated at various time points post‐infection. Serum cytokine expression was measured through cytometric bead array.Results: Oral infection of WT mice with S.Tm on days 9–10 of gestation resulted in systemic dissemination of the bacteria, substantial placental colonization, and fetal loss 5 days post‐infection. Histopathological examination of the placentas indicated that infection‐induced widespread focal necrosis and neutrophil infiltration throughout the spongiotrophoblast (SpT) layer. In the non‐pregnant state, IFNAR1−/− mice exhibited increased survival following oral S.Tm infection relative to Caspase‐1, 11−/−, RIP3−/−, and WT mice. The increased resistance to S.Tm infection in IFNAR1−/− mice was seen during pregnancy as well, with decreased bacterial burden within MLNs, spleen, and placenta, which correlated with the decreased resorptions relative to WT and Caspase‐1, 11−/− mice.Conclusion: Oral S.Tm exposure leads to placental infection, inflammation, and resorption, whereas IFNAR1 deficiency enhances host resistance both in the non‐pregnant and pregnant states.


  • Open Access

    Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model

    by Bassel Akache, Gerard Agbayani, Felicity C. Stark, Yimei Jia, Renu Dudani, Blair A. Harrison, Lise Deschatelets, Vandana Chandan, Edmond Lam, Usha D. Hemraz, et al.

    Cancer remains a leading cause of morbidity and mortality worldwide. While novel treatments have improved survival outcomes for some patients, new treatment modalities/platforms are needed to combat a wider variety of tumor types. Cancer vaccines harness the power of the immune system to generate targeted tumor-specific immune responses. Liposomes composed of glycolipids derived from archaea (i.e., archaeosomes) have been shown to be potent adjuvants, inducing robust, long-lasting humoral and cell-mediated immune responses to a variety of antigens. Herein, we evaluated the ability of archaeosomes composed of sulfated lactosyl archaeol (SLA), a semi-synthetic archaeal glycolipid, to enhance the immunogenicity of a synthetic long peptide-based vaccine formulation containing the dominant CD8+ T cell epitope, SIINFEKL, from the weakly immunogenic model antigen ovalbumin. One advantage of immunizing with long peptides is the ability to include multiple epitopes, for example, the long peptide antigen was also designed to include the immediately adjacent CD4+ epitope, TEWTSSNVMEER. SLA archaeosomes were tested alone or in combination with the toll-like receptor 3 (TLR3) agonist Poly(I:C). Overall, SLA archaeosomes synergized strongly with Poly(I:C) to induce robust antigen-specific CD8+ T cell responses, which were highly functional in an in vivo cytolytic assay. Furthermore, immunization with this vaccine formulation suppressed tumor growth and extended mouse survival in a mouse melanoma tumor model. Overall, the combination of SLA archaeosomes and Poly(I:C) appears to be a promising adjuvant system when used along with long peptide-based antigens targeting cancer.


  • Open Access

    The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model

    by Yimei Jia, Bassel Akache, Gerard Agbayani, Vandana Chandan, Renu Dudani, Blair A. Harrison, Lise Deschatelets, Usha D. Hemraz, Edmond Lam, Sophie Régnier, et al.

    Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. SLA archaeosomes are a promising adjuvant candidate due to their ability to strongly stimulate both humoral and cytotoxic immune responses when simply admixed with an antigen. In the present study, we evaluated whether the adjuvant effects of SLA archaeosomes could be further enhanced when combined with other adjuvants. SLA archaeosomes were co-administered with five different Toll-like Receptor (TLR) agonists or the saponin QS-21 using ovalbumin as a model antigen in mice. Both humoral and cellular immune responses were greatly enhanced compared to either adjuvant alone when SLA archaeosomes were combined with either the TLR3 agonist poly(I:C) or the TLR9 agonist CpG. These results were also confirmed in a separate study using Hepatitis B surface antigen (HBsAg) and support the further evaluation of these adjuvant combinations.


  • Open Access

    Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins

    by Bassel Akache, Lise Deschatelets, Blair A. Harrison, Renu Dudani, Felicity C. Stark, Yimei Jia, Amir Landi, John L. M. Law, Michael Logan, Darren Hockman, et al.

    Infection by Hepatitis C virus (HCV) can lead to liver cirrhosis/hepatocellular carcinoma and remains a major cause of serious disease morbidity and mortality worldwide. However, current treatment regimens remain inaccessible to most patients, particularly in developing countries, and, therefore, the development of a novel vaccine capable of protecting subjects from chronic infection by HCV could greatly reduce the rates of HCV infection, subsequent liver pathogenesis, and in some cases death. Herein, we evaluated two different semi-synthetic archaeosome formulations as an adjuvant to the E1/E2 HCV envelope protein in a murine model and compared antigen-specific humoral (levels of anti-E1/E2 IgG and HCV pseudoparticle neutralization) and cellular responses (numbers of antigen-specific cytokine-producing T cells) to those generated with adjuvant formulations composed of mimetics of commercial adjuvants including a squalene oil-in-water emulsion, aluminum hydroxide/monophosphoryl lipid A (MPLA) and liposome/MPLA/QS-21. In addition, we measured the longevity of these responses, tracking humoral, and cellular responses up to 6 months following vaccination. Overall, we show that the strength and longevity of anti-HCV responses can be influenced by adjuvant selection. In particular, a simple admixed sulfated S-lactosylarchaeol (SLA) archaeosome formulation generated strong levels of HCV neutralizing antibodies and polyfunctional antigen-specific CD4 T cells producing multiple cytokines such as IFN-γ, TNF-α, and IL-2. While liposome/MPLA/QS-21 as adjuvant generated superior cellular responses, the SLA E1/E2 admixed formulation was superior or equivalent to the other tested formulations in all immune parameters tested.


  • Open Access

    Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma

    by Felicity C. Stark, Gerard Agbayani, Jagdeep K. Sandhu, Bassel Akache, Charis McPherson, Lise Deschatelets, Renu Dudani, Melissa Hewitt, Yimei Jia, Lakshmi Krishnan, et al.

    Archaeosomes are liposomes composed of natural or synthetic archaeal lipids that when used as adjuvants induce strong long-lasting humoral and cell-mediated immune responses against entrapped antigens. However, traditional entrapped archaeosome formulations have only low entrapment efficiency, therefore we have developed a novel admixed formulation which offers many advantages, including reduced loss of antigen, consistency of batch-to-batch production as well as providing the option to formulate the vaccine immediately before use, which is beneficial for next generation cancer therapy platforms that include patient specific neo-antigens or for use with antigens that are less stable. Herein, we demonstrate that, when used in combination with anti-CTLA-4 and anti-PD-1 checkpoint therapy, this novel admixed archaeosome formulation, comprised of preformed sulfated lactosyl archaeol (SLA) archaeosomes admixed with OVA antigen (SLA–OVA (adm)), was as effective at inducing strong CD8+ T cell responses and protection from a B16-OVA melanoma tumor challenge as the traditionally formulated archaeosomes with encapsulated OVA protein. Furthermore, archaeosome vaccine formulations combined with anti-CTLA-4 and anti-PD-1 therapy, induced OVA-CD8+ T cells within the tumor and immunohistochemical analysis revealed the presence of CD8+ T cells associated with dying or dead tumor cells as well as within or around tumor blood vessels. Overall, archaeosomes constitute an attractive option for use with combinatorial checkpoint inhibitor cancer therapy platforms.


  • A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations

    by Yimei Jia, Bassel Akache, Lise Deschatelets, Hui Qian, Renu Dudani, Blair A. Harrison, Felicity C. Stark, Vandana Chandan, Mohammad P. Jamshidi, Lakshmi Krishnan, et al.


  • Type I interferons differentially modulate maternal host immunity to infection by Listeria monocytogenes and Salmonella enterica serovar Typhimurium during pregnancy

    by Gerard Agbayani, Kristina Wachholz, Shawn P. Murphy, Subash Sad, Lakshmi Krishnan

    Problem: IFN‐alpha receptor deficiency (IFNAR −/− ) enhances immunity to Listeria monocytogenes (LM) and Salmonella enterica serovar Typhimurium (ST) in the non‐pregnant state by inhibiting pathogen‐induced immune cell death. However, the roles of IFNAR signaling in modulating immunity to infection during pregnancy are not well understood. Method of Study: C57BL/6J wild‐type (WT) and IFNAR −/− mice were infected systemically with LM or ST. Bacterial burden in spleen and individual placentas was enumerated at day 3 post‐infection. Immune cell numbers and percentages were quantified in spleen and individual placentas, respectively, through flow cytometry. Cytokine expression in serum, spleen, and individual placentas was measured through cytometric bead array. Results: IFNAR −/− mice exhibited decreased splenic monocyte numbers in non‐pregnant and pregnant state, and an altered distribution of placental immune cell types in the non‐infected state. IFNAR −/− mice controlled LM infection more effectively than WT mice even during pregnancy. This correlated with enhanced serum IL‐12 expression, despite reduced splenic monocyte numbers relative to WT controls. In contrast, pregnant IFNAR −/− mice unlike their non‐pregnant counterparts exhibited increased susceptibility to ST infection, which was associated with decreased serum IL‐12 expression. Conclusion: Type I IFN responses differentially impact host resistance to LM and ST infection during pregnancy through modulation of immune cell distribution and cytokine responses.


  • Development of a recombinant murine tumour model using hepatoma cells expressing hepatitis C virus nonstructural antigens

    by K. G. Young, K. Haq, S. MacLean, R. Dudani, S. M. Elahi, R. Gilbert, R. D. Weeratna, L. Krishnan

    Summary: Hepatitis C virus (HCV) chronically infects 2%‐3% of the world's population, causing liver disease and cancer with prolonged infection. The narrow host range of the virus, being restricted largely to human hepatocytes, has made the development of relevant models to evaluate the efficacy of vaccines a challenge. We have developed a novel approach to accomplish this by generating a murine hepatoma cell line stably expressing nonstructural HCV antigens which can be used in vitro or in vivo to test HCV vaccine efficacies. These HCV‐recombinant hepatoma cells formed large solid‐mass tumours when implanted into syngeneic mice, allowing us to test candidate HCV vaccines to demonstrate the development of an HCV‐specific immune response that limited tumour growth. Using this model, we tested the therapeutic potential of recombinant anti‐HCV‐specific vaccines based on two fundamentally different attenuated pathogen vaccine systems—attenuated Salmonella and recombinant adenoviral vector based vaccine. While attenuated Salmonella that secreted HCV antigens limited growth of the HCV‐recombinant tumours when used in a therapeutic vaccination trial, replication‐competent but noninfectious adenovirus expressing nonstructural HCV antigens showed overall greater survival and reduced weight loss compared to non‐replicating nondisseminating adenovirus. Our results demonstrate a model with anti‐tumour responses to HCV nonstructural (NS) protein antigens and suggest that recombinant vaccine vectors should be explored as a therapeutic strategy for controlling HCV and HCV‐associated cancers.